Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:OCUL
- CUSIP: N/A
- Web: www.ocutx.com
Capitalization:- Market Cap: $179.98 million
- Outstanding Shares: 29,057,000
Average Prices:- 50 Day Moving Avg: $6.09
- 200 Day Moving Avg: $8.31
- 52 Week Range: $4.82 - $11.91
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.93
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.9 million
- Price / Sales: 96.50
- Book Value: $1.65 per share
- Price / Book: 3.82
Profitability:- EBIDTA: ($54,640,000.00)
- Net Margins: -3,005.52%
- Return on Equity: -101.03%
- Return on Assets: -69.76%
Debt:- Debt-to-Equity Ratio: 0.32%
- Current Ratio: 5.20%
- Quick Ratio: 5.20%
Misc:- Average Volume: 1.11 million shs.
- Beta: 1.6
- Short Ratio: 3.03
Frequently Asked Questions for Ocular Therapeutix (NASDAQ:OCUL)
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its earnings results on Tuesday, August, 8th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.05. The business earned $0.40 million during the quarter, compared to the consensus estimate of $0.51 million. Ocular Therapeutix had a negative return on equity of 101.03% and a negative net margin of 3,005.52%. The business's quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.46) earnings per share. View Ocular Therapeutix's Earnings History.
When will Ocular Therapeutix make its next earnings announcement?
Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?
6 equities research analysts have issued 1 year price objectives for Ocular Therapeutix's stock. Their predictions range from $8.00 to $60.00. On average, they anticipate Ocular Therapeutix's stock price to reach $24.00 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.
What are analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/23/2017)
- 2. Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Sientra (SIEN), Utah Medical Products (UTMD), Transenterix (TRXC), Transenterix (TRXC), T2 Biosystems (TTOO), SeaSpine Holdings Corporation (SPNE), Bioquell plc (BQE), Capnia (SLNO), Tandem Diabetes Care (TNDM), Surgical Innovations Group Plc (SUN), Alliqua BioMedical (ALQA), Lombard Medical (EVAR), Cytori Therapeutics (CYTX), NeuroMetrix (NURO), InspireMD (NSPR), CareFusion (CFN), Covidien Ltd (COV) and CRH Medical Corp (CRHM).
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Amarpreet Sawhney Ph.D., Executive Chairman of the Board
- James Fortune, Interim Principal Financial Officer, Chief Operating Officer, Interim Princiapl Accounting Officer
- George V. Migausky, Interim Chief Financial Officer
- Daniel M. Bollag Ph.D., Senior Vice President - Regulatory Affairs, Pharmacovigilance and Quality
- Andy Hurley, Chief Commercial Officer
- Jonathan Talamo M.D., Chief Medical Officer
- Jaswinder S. Chadha, Director
- W. James O'Shea, Director
- Jeffrey S. Heier M.D., Independent Director
- Richard L. Lindstrom M.D., Independent Director
Who owns Ocular Therapeutix stock?
Ocular Therapeutix's stock is owned by many different of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (7.63%), Jennison Associates LLC (6.84%), SV Health Investors LLC (5.53%), FMR LLC (4.56%), Vanguard Group Inc. (3.12%) and Columbus Circle Investors (1.99%). View Institutional Ownership Trends for Ocular Therapeutix.
Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?
Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Columbus Circle Investors, Deltec Asset Management LLC, FMR LLC, JPMorgan Chase & Co., Edmond DE Rothschild Holding S.A., Wells Fargo & Company MN and NEXT Financial Group Inc. View Insider Buying and Selling for Ocular Therapeutix.
Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?
Ocular Therapeutix's stock was purchased by a variety of institutional investors in the last quarter, including Cowen Inc., State Street Corp, Northern Trust Corp, Parametric Portfolio Associates LLC, Neuberger Berman Group LLC, State of Wisconsin Investment Board, Alliancebernstein L.P. and Voya Investment Management LLC. View Insider Buying and Selling for Ocular Therapeutix.
How do I buy Ocular Therapeutix stock?
Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of Ocular Therapeutix stock can currently be purchased for approximately $6.31.
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $24.00 (280.35% upside) |
Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/10/2017 | BTIG Research | Reiterated Rating | Neutral | | Low |  |
| 8/9/2017 | HC Wainwright | Reiterated Rating | Buy | $10.00 | High | |
| 7/14/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $16.00 -> $8.00 | Low | |
| 7/12/2017 | Cantor Fitzgerald | Lower Price Target | Overweight -> Overweight | $35.00 -> $21.00 | High | |
| 3/13/2017 | Cowen and Company | Reiterated Rating | Outperform | $60.00 | Medium | |
| 11/15/2016 | Royal Bank Of Canada | Reiterated Rating | Outperform | $30.00 -> $32.00 | N/A | |
| 8/11/2016 | JMP Securities | Initiated Coverage | Outperform | $21.00 -> $5.84 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Ocular Therapeutix (NASDAQ:OCUL)Earnings History by Quarter for Ocular Therapeutix (NASDAQ OCUL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.54) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.59) | ($0.64) | $0.51 million | $0.40 million | View | Listen | |
| 5/5/2017 | Q1 2017 | ($0.48) | ($0.58) | $0.51 million | $0.48 million | View | N/A | |
| 3/10/2017 | Q4 2016 | ($0.45) | ($0.52) | $0.48 million | $0.51 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.50) | ($0.39) | $0.47 million | $0.48 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.49) | ($0.46) | $0.55 million | $0.44 million | View | Listen | |
| 5/10/2016 | Q116 | ($0.43) | ($0.44) | | $458.00 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.47) | ($0.43) | | $0.44 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.38) | ($0.47) | | $0.43 million | View | Listen | |
| 8/10/2015 | Q215 | ($0.33) | ($0.45) | | $0.46 million | View | Listen | |
| 5/15/2015 | Q115 | ($0.39) | ($0.35) | $0.30 million | $0.43 million | View | Listen | |
| 3/10/2015 | Q4 | ($0.38) | ($0.37) | $0.20 million | $0.51 million | View | Listen | |
| 11/12/2014 | Q3 14 | ($0.55) | ($0.48) | $0.10 million | $0.14 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)Current Year EPS Consensus Estimate: $-2.27 EPS
Next Year EPS Consensus Estimate: $-2.15 EPS
Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ocular Therapeutix (NASDAQ:OCUL)Insider Ownership Percentage: 26.10%
Institutional Ownership Percentage: 53.42%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/15/2016 | Amarpreet Sawhney | Insider | Buy | 45,300 | $7.85 | $355,605.00 | |
| 6/9/2016 | Amarpreet Sawhney | CEO | Buy | 10,000 | $6.70 | $67,000.00 | |
| 11/17/2015 | Amarpreet Sawhney | CEO | Buy | 10,000 | $8.25 | $82,500.00 | |
| 9/15/2015 | James Fortune | COO | Sell | 9,470 | $17.16 | $162,505.20 | |
| 9/14/2015 | Amarpreet Sawhney | CEO | Buy | 15,000 | $16.50 | $247,500.00 | |
| 6/15/2015 | Charles M Warden | Director | Sell | 320,000 | $22.00 | $7,040,000.00 | |
| 6/10/2015 | Charles M Warden | Director | Sell | 427,000 | $22.00 | $9,394,000.00 | |
| 6/10/2015 | Svlsf Iv, Llc | Major Shareholder | Sell | 1,119,000 | $22.00 | $24,618,000.00 | |
| 7/30/2014 | Amarpreet Sawhney | CEO | Buy | 76,922 | $13.00 | $999,986.00 | |
| 7/30/2014 | Svlsf Iv, Llc | Major Shareholder | Buy | 715,380 | $13.00 | $9,299,940.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ocular Therapeutix (NASDAQ:OCUL)
Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
| Source: |
|
| Date | Headline |
|---|
 | Head-To-Head Comparison: K2M Group Holdings (KTWO) and Ocular Therapeutix (OCUL)
www.americanbankingnews.com - September 19 at 2:30 PM |
| Ocular Therapeutix (OCUL) vs. Steris Plc (STE) Financial Survey
www.americanbankingnews.com - September 15 at 2:30 PM |
 | Have Investors Already Priced In Ocular Therapeutix Inc’s (OCUL) Growth?
finance.yahoo.com - September 14 at 8:40 AM |
 | Ocular Therapeutix (OCUL) Appoints Michael Goldstein as CMO - StreetInsider.com
www.streetinsider.com - September 10 at 5:35 AM |
| Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer
finance.yahoo.com - September 9 at 6:58 AM |
 | Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences - Business Wire (press release)
www.businesswire.com - September 7 at 7:10 AM |
| Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
finance.yahoo.com - September 7 at 7:10 AM |
| FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - September 6 at 7:10 AM |
| OCUL DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - September 6 at 7:10 AM |
| DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - September 2 at 7:01 AM |
| UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - September 2 at 7:01 AM |
| DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ocular Therapeutix, Inc. (Nasdaq:OCUL) To Contact The Firm
finance.yahoo.com - September 2 at 7:01 AM |
| FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - September 2 at 7:01 AM |
| DEADLINE TUESDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
finance.yahoo.com - September 2 at 7:01 AM |
| DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 2 at 7:01 AM |
| Ocular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 2 at 4:40 AM |
 | 5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc ... - GlobeNewswire (press release)
globenewswire.com - September 1 at 6:40 AM |
| 5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 1 at 6:40 AM |
| OCUL EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - August 31 at 8:12 AM |
| SEPTEMBER 5 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - August 31 at 8:11 AM |
| Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocular Therapeutix, Inc. (OCUL) and Encourages Investors with Losses to Contact the Firm Before September 5, 2017
finance.yahoo.com - August 29 at 6:15 AM |
 | DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - August 28 at 3:49 PM |
| Research Analysts Offer Predictions for Ocular Therapeutix Inc's FY2017 Earnings (OCUL)
www.americanbankingnews.com - August 28 at 2:52 AM |
 | Bernstein Liebhard LLP Announces That Only 10 Days Remain To File A Motion For Lead Plaintiff In A Class Action ... - PR Newswire (press release)
www.prnewswire.com - August 27 at 4:16 AM |
| Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocular Therapeutix, Inc. - Business Wire (press release)
www.businesswire.com - August 26 at 7:58 AM |
| Bernstein Liebhard LLP Announces That Only 10 Days Remain To File A Motion For Lead Plaintiff In A Class Action Filed Against Ocular Therapeutix, Inc.
finance.yahoo.com - August 26 at 7:58 AM |
| Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocular Therapeutix, Inc.
finance.yahoo.com - August 26 at 7:58 AM |
| OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm
finance.yahoo.com - August 26 at 7:58 AM |
| DEADLINE APPROACHING: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - August 26 at 7:58 AM |
| DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - August 25 at 9:35 AM |
| OCUL ALERT: Rosen Law Firm Reminds Ocular Therapeutix, Inc. Investors of Important Deadline in First Filed Class Action - OCUL
feeds.benzinga.com - August 24 at 7:41 PM |
| INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 24 at 10:29 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - August 24 at 10:29 AM |
| OCUL Investors Deadline Reminder: Hagens Berman Reminds Investors in Ocular Therapeutix, Inc. of the September 5, 2017 Lead Plaintiff Deadline in the Pending Securities Class Action
finance.yahoo.com - August 24 at 10:29 AM |
| DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - August 24 at 10:29 AM |
| DEADLINE ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 24 at 10:29 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 24 at 10:29 AM |
| Financial Contrast: Ocular Therapeutix (OCUL) vs. Tandem Diabetes Care (TNDM)
www.americanbankingnews.com - August 24 at 8:38 AM |
| Bragar Eagel & Squire, PC Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocular Therapeutix ... - Business Wire (press release)
www.businesswire.com - August 23 at 9:38 AM |
| Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocular Therapeutix, Inc. (OCUL) and Encourages Investors with Losses to Contact ...
www.businesswire.com - August 22 at 1:22 AM |
| Analyzing Transenterix (TRXC) and Ocular Therapeutix (OCUL)
www.americanbankingnews.com - August 21 at 8:09 AM |
| INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 19 at 6:09 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 19 at 6:09 AM |
| DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 19 at 6:09 AM |
| APPROACHING DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 10:03 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 17 at 5:01 PM |
| EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 5:01 PM |
| INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 17 at 5:01 PM |
| The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
finance.yahoo.com - August 17 at 5:01 PM |
| SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 6:25 AM |
Ocular Therapeutix (OCUL) Chart for Thursday, September, 21, 2017
